GEVA - Synageva Biopharma Corp Stock Price, News & Analysis

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

About Synageva Biopharma Corp (NASDAQ:GEVA)

Synageva Biopharma Corp logoSynageva BioPharma Corp. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for the treatment of rare diseases. The Company has a pipeline of protein therapeutic programs for rare diseases. Its lead product is Kanuma (sebelipase alfa) being developed for the treatment of lysosomal acid lipase deficiency (LAL Deficiency). The Company's other product candidates under development include SBC-103, a first-mover enzyme replacement therapy program for mucopolysaccharidosis IIIB (MPS IIIB, also known as Sanfilippo B syndrome) and SBC-105, which is a first-mover enzyme therapy in preclinical development for rare disorders of calcification, including the indication generalized calcification in infants (GACI). The Company also has additional first-mover and potentially bio-superior protein therapeutic pipeline programs for other rare diseases at different stages of preclinical development.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Annual DividendN/A
Dividend YieldN/A


Trailing EPS($6.34)
Net IncomeN/A
Net Margins-6,429.45%
Return on Equity-39.57%
Return on Assets-37.57%


Outstanding SharesN/A

Frequently Asked Questions for Synageva Biopharma Corp (NASDAQ:GEVA)

What is Synageva Biopharma Corp's stock symbol?

Synageva Biopharma Corp trades on the NASDAQ under the ticker symbol "GEVA."

How were Synageva Biopharma Corp's earnings last quarter?

Synageva Biopharma Corp (NASDAQ:GEVA) announced its earnings results on Thursday, February, 26th. The biopharmaceutical company reported ($1.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.71) by $0.02. The biopharmaceutical company had revenue of $1.24 million for the quarter, compared to analyst estimates of $1.25 million. Synageva Biopharma Corp had a negative return on equity of 39.57% and a negative net margin of 6,429.45%. View Synageva Biopharma Corp's Earnings History.

Who are some of Synageva Biopharma Corp's key competitors?

How do I buy Synageva Biopharma Corp stock?

Shares of Synageva Biopharma Corp can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Synageva Biopharma Corp?

Synageva Biopharma Corp's mailing address is 33 Hayden Ave, LEXINGTON, MA 02421-7972, United States. The biopharmaceutical company can be reached via phone at +1-781-3579900.

MarketBeat Community Rating for Synageva Biopharma Corp (GEVA)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  137 (Vote Outperform)
Underperform Votes:  104 (Vote Underperform)
Total Votes:  241
MarketBeat's community ratings are surveys of what our community members think about Synageva Biopharma Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Synageva Biopharma Corp (NASDAQ:GEVA)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for Synageva Biopharma Corp (NASDAQ:GEVA)

Price Target History for Synageva Biopharma Corp (NASDAQ:GEVA)

Analysts' Ratings History for Synageva Biopharma Corp (NASDAQ:GEVA)

DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/28/2016WedbushBoost Price TargetNeutral$67.00 -> $93.00N/AView Rating Details
(Data available from 11/23/2015 forward)


Earnings History and Estimates Chart for Synageva Biopharma Corp (NASDAQ:GEVA)

Earnings by Quarter for Synageva Biopharma Corp (NASDAQ:GEVA)

Earnings History by Quarter for Synageva Biopharma Corp (NASDAQ GEVA)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2015Q114($1.71)($1.73)$1.25 million$1.24 millionViewListenView Earnings Details
10/30/2014Q3 2014($1.61)($1.46)$1.40 million$1.33 millionViewN/AView Earnings Details
7/30/2014Q2 2014($1.37)($1.52)$1.43 million$2.34 millionViewN/AView Earnings Details
4/30/2014Q1 2014($1.19)($1.16)$1.86 million$1.59 millionViewN/AView Earnings Details
3/3/2014Q4 13($1.02)($1.00)$4.88 million$3.47 millionViewN/AView Earnings Details
8/5/2013Q2 2013($0.76)($0.81)$2.90 million$3.41 millionViewN/AView Earnings Details
3/11/2013Q4 2012($0.60)($0.62)$2.32 million$2.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Synageva Biopharma Corp (NASDAQ:GEVA)

No earnings estimates for this company have been tracked by


Dividend History for Synageva Biopharma Corp (NASDAQ:GEVA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Synageva Biopharma Corp (NASDAQ GEVA)

Insider Trades by Quarter for Synageva Biopharma Corp (NASDAQ:GEVA)

Insider Trades by Quarter for Synageva Biopharma Corp (NASDAQ GEVA)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/8/2015Glen WilliamsSVPSell12,916$214.92$2,775,906.72View SEC Filing  
4/27/2015Anthony QuinnCMOSell10,000$110.00$1,100,000.00View SEC Filing  
4/21/2015Anthony QuinnCMOSell10,000$108.00$1,080,000.00View SEC Filing  
4/15/2015Anthony QuinnCMOSell10,000$105.00$1,050,000.00View SEC Filing  
4/8/2015Glen WilliamsSVPSell42,632$96.08$4,096,082.56View SEC Filing  
4/6/2015Anthony QuinnCMOSell29,503$93.76$2,766,201.28View SEC Filing  
1/7/2015Julian BakerDirectorBuy1,000,000$94.19$94,190,000.00View SEC Filing  
12/29/2014Chris HeberligVPSell6,100$91.14$555,954.00View SEC Filing  
12/17/2014Sanj K PatelCEOSell50,000$88.85$4,442,500.00View SEC Filing  
10/30/2014Carsten BoessCFOSell25,404$80.10$2,034,860.40View SEC Filing  
9/19/2014Mark Alan GoldbergEVPSell790$65.24$51,539.60View SEC Filing  
9/17/2014Mark Alan GoldbergEVPSell13,579$65.03$883,042.37View SEC Filing  
9/2/2014Anthony QuinnCMOSell10,000$70.14$701,400.00View SEC Filing  
6/20/2014Barry D QuartDirectorSell1,375$100.00$137,500.00View SEC Filing  
6/17/2014Barry D QuartDirectorSell1,000$90.00$90,000.00View SEC Filing  
6/12/2014Barry D QuartDirectorSell1,000$83.31$83,310.00View SEC Filing  
6/11/2014Mark Alan GoldbergEVPSell21,597$80.00$1,727,760.00View SEC Filing  
5/16/2014Carsten BoessCFOSell9,927$81.94$813,418.38View SEC Filing  
4/1/2014Anthony QuinnCMOSell20,000$83.53$1,670,600.00View SEC Filing  
3/12/2014Chris HeberligVPSell7,670$98.56$755,955.20View SEC Filing  
3/6/2014Felix BakerDirectorBuy375,000$105.75$39,656,250.00View SEC Filing  
1/29/2014Sanj PatelCEOSell102,300$88.12$9,014,676.00View SEC Filing  
12/3/2013Mark Alan GoldbergSVPSell7,000$60.52$423,640.00View SEC Filing  
11/1/2013Mark Alan GoldbergSVPSell7,000$49.96$349,720.00View SEC Filing  
9/25/2013Julian BakerDirectorBuy1,050,000$56.63$59,461,500.00View SEC Filing  
8/21/2013Carsten BoessCFOSell14,481$47.11$682,199.91View SEC Filing  
8/16/2013Carsten BoessCFOSell4,300$47.47$204,121.00View SEC Filing  
7/29/2013Sanj K PatelCEOSell100,000$48.02$4,802,000.00View SEC Filing  
7/16/2013Chris HeberligVPSell2,524$48.43$122,237.32View SEC Filing  
7/11/2013Carsten BoessCFOSell13,237$47.06$622,933.22View SEC Filing  
6/12/2013Sanj K PatelCEOSell70,000$40.65$2,845,500.00View SEC Filing  
2/1/2013Mark Alan GoldbergSVPSell4,417$47.75$210,911.75View SEC Filing  
1/17/2013Anthony QuinnSVPSell5,553$50.07$278,038.71View SEC Filing  
1/16/2013Carsten BoessCFOSell9,927$49.12$487,614.24View SEC Filing  
1/9/2013Thomas J TischDirectorBuy21,039$47.53$999,983.67View SEC Filing  
1/4/2013Julian BakerDirectorBuy859,720$47.53$40,862,491.60View SEC Filing  
9/4/2012Chris HeberligVPSell1,000$49.10$49,100.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Synageva Biopharma Corp (NASDAQ GEVA)


Social Media



Synageva Biopharma Corp (NASDAQ GEVA) Chart for Thursday, November, 23, 2017
Loading chart…

This page was last updated on 11/23/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.